Equities analysts expect Cambrex Co. (NYSE:CBM) to report earnings of $0.31 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Cambrex’s earnings, with the highest EPS estimate coming in at $0.53 and the lowest estimate coming in at $0.08. Cambrex reported earnings of $0.68 per share during the same quarter last year, which would indicate a negative year over year growth rate of 54.4%. The business is scheduled to issue its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Cambrex will report full-year earnings of $2.92 per share for the current financial year, with EPS estimates ranging from $2.90 to $2.94. For the next year, analysts anticipate that the company will report earnings of $3.14 per share, with EPS estimates ranging from $3.01 to $3.30. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Cambrex.
Cambrex (NYSE:CBM) last posted its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.17. The business had revenue of $182.28 million during the quarter, compared to analyst estimates of $181.39 million. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.23 EPS.
Several research analysts have recently commented on the company. Zacks Investment Research raised Cambrex from a “sell” rating to a “hold” rating in a report on Wednesday, April 11th. Longbow Research lowered Cambrex from a “buy” rating to a “neutral” rating in a report on Wednesday, February 14th. Finally, William Blair assumed coverage on Cambrex in a report on Tuesday, January 16th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $60.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Financial Gravity Companies Inc. purchased a new position in shares of Cambrex during the fourth quarter worth about $166,000. Visionary Asset Management Inc. purchased a new position in shares of Cambrex during the third quarter worth about $201,000. Elkfork Partners LLC purchased a new position in shares of Cambrex during the fourth quarter worth about $202,000. MML Investors Services LLC purchased a new position in shares of Cambrex during the fourth quarter worth about $204,000. Finally, Two Sigma Securities LLC purchased a new position in shares of Cambrex during the fourth quarter worth about $207,000.
Shares of NYSE CBM traded up $0.45 during midday trading on Monday, hitting $54.85. 42,018 shares of the company’s stock were exchanged, compared to its average volume of 305,680. Cambrex has a 12-month low of $42.55 and a 12-month high of $62.95. The firm has a market capitalization of $1,786.87, a price-to-earnings ratio of 17.30, a PEG ratio of 1.29 and a beta of 2.32.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/16/zacks-analysts-anticipate-cambrex-co-cbm-to-post-0-31-eps.html.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Get a free copy of the Zacks research report on Cambrex (CBM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.